跳至主要内容
临床试验/NCT01083290
NCT01083290已完成1 期

Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg Tablets in Healthy Subjects Under Fasting Conditions.

Orion Corporation, Orion Pharma1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2010年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
14
试验地点
1
主要终点
Cmax, AUC0-t and AUC0-inf of Spironolactone and its metabolites canrenone and 7α-thiomethylspirolactone in plasma

研究概览

简要总结

Objective is to investigate pharmacokinetics and to estimate the level of dose linearity of spironolactone and its metabolites canrenone and 7α-thiomethylspirolactone from Spironolactone 25 mg, 50 mg and 100 mg Tablets

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects with normal findings as determined by baseline history, physical examination and vital signs, haemogram, biochemistry, infectious disease screening, urinalysis, 12 lead ECG

排除标准

  • Any condition requiring regular concomitant medication or likely to need any concomitant medication during the study.

研究组 & 干预措施

Order of strenghts; 25 mg, 50 mg, 100 mg

Experimental

干预措施: Spironolactone (Drug)

Order of strenghts; 50 mg, 100 mg, 25 mg

Experimental

干预措施: Spironolactone (Drug)

Order of strenghts; 100 mg, 25 mg, 50 mg

Experimental

干预措施: Spironolactone (Drug)

结局指标

主要结局

Cmax, AUC0-t and AUC0-inf of Spironolactone and its metabolites canrenone and 7α-thiomethylspirolactone in plasma

时间窗: up to 72 h after the study drug administration

次要结局

未报告次要终点

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验